Document is current
Any future updates will be listed below
-
Authors
Nilavar, Namrata M https://orcid.org/0000-0001-6081-0513
Marin-Gonzalez, Alberto
Menghi, Francesca
Nguyen, Daniel
Willis, Nicholas A
Wientjens, Ellen
Xia, Bing https://orcid.org/0000-0003-3259-6139
Jonkers, Jos https://orcid.org/0000-0002-9264-9792
Liu, Edison T
Scully, Ralph https://orcid.org/0000-0002-5064-0175
-
Funding
Funding for this research was provided by:
HHS | NIH | National Cancer Institute (R35CA263813)
HHS | NIH | National Cancer Institute (P30CA034196)
HHS | NIH | National Cancer Institute (R01CA255705)
HHS | NIH | National Cancer Institute (R01CA138804)
HHS | NIH | National Cancer Institute (R01CA262227)
HHS | NIH | National Cancer Institute (P01CA250957)
Oncode Institute
Lundbeck Foundation (R223-2016-8)
American Cancer Society (PF-24-1321213-01-DMC)
KWF Kankerbestrijding (NKI 2015-7877)
- License Information
-
More Information
Article History
Received: 18 February 2026
Revised: 5 September 2026
Accepted: 7 September 2026
First Online: 18 September 2026
Disclosure and competing interests statement
: RS is a member of the Scientific Advisory Board of MoMa Therapeutics, Inc.
